Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

theguardian.com - Guardian staff reporter - Purdue Pharma expected to forfeit $225m as sentence in criminal opioids case
Purdue Pharma expected to forfeit $225m as sentence in criminal opioids case
The Guardian

A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225m to the US justice department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid crisis.

pbs.org - A criminal sentence for OxyContin maker Purdue Pharma clears the way for finalizing its settlement
A criminal sentence for OxyContin maker Purdue Pharma clears the way for finalizing its settlement
PBS

A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid…

independent.co.uk - Geoff Mulvihill - Purdue Pharma to be sentenced in criminal opioids case, allowing settlement money to flow
Purdue Pharma to be sentenced in criminal opioids case, allowing settlement money to flow
The Independent

A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid…

winnipegfreepress.com - Geoff Mulvihill, The Associated Press - Purdue Pharma to be sentenced in criminal opioids case, allowing settlement money to flow
Purdue Pharma to be sentenced in criminal opioids case, allowing settlement money to flow
Winnipeg Free Press

Email Address: I agree to the Terms and Conditions, Cookie and Privacy Policies, and CASL agreement. Already have an account? Log in here - To continue reading, please subscribe: Enjoy unlimited reading on winnipegfreepress.com Read the E-Edition…

wcvb.com - GEOFF MULVIHILL Associated Press - Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person
Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person
WCVB

Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person AGAINST THE OPIOID CRISIS. AT THE UPPER ROOM FAMILY RESOURCE CENTER IN DERRY, THEIR MISSION HAS ALWAYS BEEN SIMPLE SUPPORT FAMILIES WHO NEED A PLACE…

thehindubusinessline.com - Pharma exporters facing issues with Online National Drug Licensing System
Pharma exporters facing issues with Online National Drug Licensing System
BusinessLine

The pharmaceutical exporters are facing some issues in the Online National Drug Licensing System (ONDLS) being implemented for the issue of Certificates of Pharmaceutical Products (COPP) under the World Health Organisation's Good Manufacturing…

statnews.com - Ed Silverman - Pharmalittle: We're reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more
Pharmalittle: We're reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more
STAT

Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again. And to celebrate, we are brewing another cuppa stimulation and inviting you to join us. Our choice today is blackberry…

nbcconnecticut.com - Geoff Mulvihill | The Associated Press - Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person
Judge postpones OxyContin-maker Purdue Pharma's sentencing to let opioid victims attend in person
NBC Connecticut

A judge on Tuesday delayed the criminal sentencing of OxyContin maker Purdue Pharma in order to allow victims to attend the court proceeding in person. U.S. District Judge Madeline Cox Arleo was originally planning to hand down the sentence Tuesday…

marketbeat.com - Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Up 8.2% - Should You Buy?
Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Up 8.2% - Should You Buy?
MarketBeat

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price was up 8.2% during trading on Tuesday. The company traded as high as $49.35 and last traded at $49.35. Approximately 1,000 shares traded hands during trading, a decline of 78% from…

marketbeat.com - Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of 'Buy' from Analysts
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of 'Buy' from Analysts
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) has been assigned a consensus rating of 'Buy' from the six brokerages that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy…

statnews.com - Andrew Joseph - With successful trials, Roche takes its MS drug to regulators, but safety questions loom
With successful trials, Roche takes its MS drug to regulators, but safety questions loom
STAT

The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for a medicine that it believes can cut relapse rates and slow the progressive…

japantimes.co.jp - Saritha Rai - Japanet expands its VC fund after bets on Anthropic and xAI pay off
Japanet expands its VC fund after bets on Anthropic and xAI pay off
The Japan Times

Japanese home shopping company Japanet is expanding its venture capital fund with San Jose-based Pegasus Tech Ventures, following the success of early bets in SpaceX, OpenAI, Anthropic and xAI. The Nagasaki-based retailer known for infomercials…

forbes.com - Trefis Team - Is McKesson Stock Still A High-Conviction Compounder?
Is McKesson Stock Still A High-Conviction Compounder?
Forbes

McKesson's net earnings increased at an average rate of 14.4% over the previous three years, while its earnings per share (EPS) grew by 19.6% annually in that same period. This 5.2% disparity indicates the additional value management has…

seekingalpha.com - Albert Anthony - Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential (AMRX)
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential (AMRX)
Seeking Alpha

Amneal Pharmaceuticals, Inc. remains a Buy, driven by robust top-line growth, a diversified drug pipeline, and macro demand in key clinical areas. AMRX's FY2025 revenue grew 8% to $3.02B, with positive FY26 guidance and outperformance of Crexont…

forbes.com - Catherine Brock - 5 Best Stocks To Buy Now For May 2026
5 Best Stocks To Buy Now For May 2026
Forbes

Investor uses mobile phone and laptop to analyze stock market while sitting at desk and reviewing charts. The best stocks to buy in May are defensive stocks. Consumers are feeling the pressures of economic uncertainty, according to the University…

Receive a Daily briefing on Pharma Industry News

Get Started